Paradigm completes Phase 3 enrolment as Zilosul trial moves toward interim analysis
· themarketherald.com.au
Paradigm Biopharmaceuticals has completed enrolment in its Phase 3 knee osteoarthritis trial, with top-line results expected in Q1 2027.
Join our daily newsletter At The Bell to receive exclusive market insights
Paradigm Biopharmaceuticals (ASX:PAR) has completed enrolment in its pivotal global ...